Pilot study of 12 outpatients in early recovery from illicit drug use,post-detox and on
buprenorphine-naloxone maintenance will be offered 12 TEAS adjunct treatments over 6
weeks(X2/week) to ascertain if they experience any improvement in mood,sleep,overall quality
of life and decrease drug cravings ultimately while facing everyday life stressors.
- this crossover study will involve participants who will be randomized into two
treatment groups,A&B. TEAS treatments will be given for 30 minutes,X2/week,for 6
weeks(12total sessions). Group A will receive 2 weeks(4 sessions) of active treatment
followed by 4 weeks of sham treatment(8 sessions). Group B will receive 2 weeks(4
sessions) of sham treatment,2 weeks (4 sessions)of real treatment,and finally 2 weeks
(4 sessions) of sham treatment.
- parameters to be measured include vital signs and questionnaires weeks 1,3,5,6 to
assess self-reported past 14-day substance use,alcohol and drug craving,withdrawal
symptoms,sleep,mood,pain and overall quality of life.
- goals include better lives for post-detox opiate addicts as they incorporate this
treatment into their lives,saving themselves and loved ones more horror,and their
- 18-59 years old
- early recovery(0-3months of abstinence
- not currently detoxing
- maintained on buprenorphine-naloxone under the care of qualified MD
- proficient in the English language
- having acute,psychiatric symptoms which would pose safety concerns,or an adherence to
treatment barrier(active suicidality/psychosis/mania)
- severe cognitive disorders*not competent to give informed consent
- active cardiac disease or EKG abnormalities or with cardiac pacemaker
- currently detoxing from alcohol or illicit drugs
- inability or non-intention to attend all treatment sessions*history of
seizures*pregnancy or breast feeding.
Barbara A MacIntyre, MSN,RN
Barbara A MacIntyre, MSN, RN